Solventum Corporation (SOLV) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, SOLV scores 45 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." Across the five pillars, the Fundamental Cash Engine scores 8 out of 20, citing ROIC of 18.7% alongside an FCF yield of -0.07%. This is the weakest pillar and signals that high accounting returns are not translating into free cash generation. Whale/13F Flow scores 9 out of 20, reflecting institutional accumulation and options positioning as a modest support. Insider Conviction scores 10 out of 20 on SEC Form 4 and Congressional PTR cluster flow, the strongest pillar but still below midpoint. Macro Regime Fit scores 9 out of 20 with a Beta of 1.06, indicating market-like volatility with limited defensive offset. Forensic Balance Sheet scores 9 out of 20, anchored by an Altman Z of 2.25, a Piotroski F-Score of 6 out of 9, and Debt/Equity of 1.

For a prospective investor, the upside case rests on the valuation discount implied by a P/E (TTM) of 9.1 and a Forward P/E of 8.5, against a 52-week range of $62.38 to $94.16. The tradeoff is that the cash engine and forensic pillars both score poorly, meaning the apparent earnings cheapness is not yet confirmed by cash flow. The RQD framing therefore points to caution: the stock may screen inexpensive on earnings, while the cash and accounting signals warrant skepticism before treating that discount as durable value.

Solventum Corporation (SOLV) is a NYSE-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. Per the profile, the company carries a market capitalization of $14.2B. Not available in source data for detailed product lines, customer segments, or revenue mechanics beyond the sector and industry classification and reported financial figures.

Per the market data, gross margin is 53.5%, operating margin 26.2%, and net margin 18.7%, with ROIC at 18.7%. Per the RQD rating, the Altman Z-Score is 2.25 and the Piotroski F-Score is 6 out of 9, with Debt/Equity of 1. Reported debt moved from $2301.7M in FY 2023 to $7810.0M in FY 2024 and $5035.0M in FY 2025, while FY 2025 free cash flow turned to $-10.0M despite higher net income, which the market data's FCF yield of -0.07% corroborates.

Recent wire items, all tagged to SOLV, include a Yahoo Finance and MarketBeat coverage pieces on market action and institutional positioning, and a Stock Titan notice that Solventum will discuss quarterly results at 4:30 p.m. Eastern on Nov. 5. A separate Stock Titan item reports that the FDA cleared two wound treatments for combined use, which may allow fewer dressing changes. A Stock Traders Daily piece addresses volatility zones as tactical triggers. None of these items carry quantitative figures in the source data.

Per the Butterfly Supply-Chain Graph, the proprietary signal is an ACCOUNTING_MIRAGE flagged as ACCRUAL & WORKING CAPITAL WATCH, with a severity score of 87 and a BEARISH direction. The signal states that Net Income growth of +220.0% diverged from Operating Cash Flow growth of -68.9%, a Cash Conversion Gap of +288.9%, with non-cash current assets and receivables expanding +19.0% relative to revenue growth. The risk watch item is the upcoming 10-Q cash realization.

Per the Butterfly Supply-Chain Graph, supply chain status is NONE and there are no butterfly links, so no upstream or downstream dependencies are mapped in the source data. Sector correlations beyond the Health Care and Medical/Dental Instruments classification are not available in source data. The principal 2nd-order watch item is the accrual gap: if receivables and working-capital builds do not reverse, the earnings-to-cash divergence could persist into the next reporting cycle and pressure the forensic and cash-engine pillars further.

• What is the cause of the divergence between FY 2025 net income of $1556.0M and FCF of $-10.0M, and how much is working-capital driven?
• What was the reported EPS for each period, given EPS is listed as N/A across all three years?
• What drove the reduction in reported debt from $7810.0M to $5035.0M between FY 2024 and FY 2025?
• What are the revenue and cash flow contributions from the FDA-cleared wound treatments, if any?
• What do the upcoming Nov. 5 quarterly results show for operating cash flow relative to net income?